bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
3.920
-0.060 (-1.51%)
At close: Apr 2, 2026, 4:00 PM EDT
3.770
-0.150 (-3.83%)
After-hours: Apr 2, 2026, 7:59 PM EDT
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
57
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$108,105
Profits / Employee
-$261,575
Market Cap
17.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57 | 0 | - |
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inotiv | 2,046 |
| FONAR | 535 |
| XWELL | 312 |
| MDxHealth | 312 |
| Exagen | 220 |
| Precipio | 60 |
| Insight Molecular Diagnostics | 49 |
| Advanced Biomed | 31 |
BIAF News
- 2 days ago - bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 - Business Wire
- 9 days ago - bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice - Business Wire
- 17 days ago - New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures - Business Wire
- 21 days ago - bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
- 21 days ago - bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - Business Wire
- 24 days ago - bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic - Business Wire
- 4 weeks ago - bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients - Business Wire
- 5 weeks ago - bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test - Business Wire